Takeda recognized as global top employer for fifth consecutive year

• Takeda has been named a Top Employer by the Top Employers Institute®, recognized for its unwavering commitment to its team members in four regions and 39 countries
• Takeda is one of only 11 companies to receive the global certification in 2022 

Dubai, United Arab Emirates: Takeda, the R&D-driven global biopharmaceutical company, has been recognized as a Global Top Employer by the Top Employers Institute for outstanding people policies and practices worldwide. One of only 11 companies worldwide to receive the global certification for 2022, it is the fifth consecutive year that Takeda has received the title. In addition to being recognized as a Top Employer globally, 39 Takeda offices around the globe also received Top Employer Status, including the UAE and Saudi Arabia in the Middle East.

The UAE and Saudi Arabia are part of Takeda’s Middle East cluster, which belong to the ICMEA (India, the Commonwealth of Independent States, Middle East, Turkey and Africa) Area. Operations in the Middle East began in 1991 with the launch of the Saudi Arabia offices, with the UAE launching in 2009.

On receiving the latest certification, Rodrigo Rodriguez, General Manager, Middle East Cluster, Takeda, said “This accolade from Top Employers Institute recognizes the efforts we have made in ensuring that our workplace culture rooted in the values of integrity, fairness, honesty and perseverance. Led by these values, the team is ensuing our abilities to deliver life-transforming treatments to those who need them most. I am especially proud of all our colleagues for remaining steadfast in their commitment to Takeda despite the challenging conditions posed by the pandemic over the past few years. As a Top Employer for the fifth consecutive year, existing and prospective employees can be confident that the Takeda family is a nourishing people-focused organization.” 

The Top Employers Institute program certifies organizations based on the participation and results of their HR Best Practices Survey. The survey covers 20 people-centric topic areas, including Career Development, Culture, Diversity & Inclusion, Learning, Sustainability, Values, Well-being and Work Environment. Takeda excelled in the categories of ethics and integrity, values, business strategy, organization and change and employer branding. For more than 30 years, Top Employers Institute has been recognizing companies that provide an outstanding culture, work environment, benefits and opportunities for their people.

-Ends-

About Takeda Pharmaceuticals

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com 

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/  or at www.sec.gov . Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

For more information
Veroniqua Khachan
E: veroniqua.khachan@fleishman.com 

© Press Release 2022